Objective:To evaluate the predictive value of secreted phosphoprotein 1(SPP1)gene expression for postoperative survival in patients with advanced liver cancer undergoing hepatic artery interventional chemoembolization...Objective:To evaluate the predictive value of secreted phosphoprotein 1(SPP1)gene expression for postoperative survival in patients with advanced liver cancer undergoing hepatic artery interventional chemoembolization treatment.Method:Bioinformatics methods,including gene ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway analysis,were used to identify genes related to survival prognosis in hepatocellular carcinoma(HCC)patients.A retrospective analysis of 115 advanced liver cancer patients treated between January 2016 and October 2017 was conducted.Patients were categorized into SPP1 high-expression(n=89)and low-expression groups(n=26).Additionally,115 healthy individuals served as the control group.The relationship between SPP1 expression and clinical pathological features was analyzed.A 60-month follow-up and logistic regression analysis identified risk factors affecting survival.Results:SPP1 mRNA expression was significantly higher in liver cancer patients compared to healthy controls(P<0.05).SPP1 expression levels were significantly associated with tumor size,Child-Pugh grading,lymph node metastasis,and BCLC staging(P<0.05).High SPP1 expression,along with tumor size,Child-Pugh grading,lymph node metastasis,and BCLC staging,were independent risk factors for survival(P<0.05).The 60-month survival rate was 17.39%,with a median survival of 40 months in the low-expression group versus 18 months in the high-expression group(P<0.05).Conclusion:SPP1 expression is significantly upregulated in advanced liver cancer patients and has predictive value for postoperative survival following hepatic artery chemoembolization treatment.SPP1,combined with clinical indicators such as tumor size,Child-Pugh grading,lymph node metastasis,and BCLC staging,may serve as a prognostic biomarker for interventional treatment outcomes.展开更多
Objective:To observe the control effect of interventional therapy combined with lenvatinib and sintilimab in patients with intermediate and advanced liver cancer.Methods:82 patients with intermediate and advanced live...Objective:To observe the control effect of interventional therapy combined with lenvatinib and sintilimab in patients with intermediate and advanced liver cancer.Methods:82 patients with intermediate and advanced liver cancer who visited from January 2022 to January 2025 were selected as samples and randomly divided into two groups.Group A received interventional therapy combined with lenvatinib and sintilimab,while Group B received interventional therapy combined with lenvatinib.Disease remission rate,adverse reactions,liver function indicators,and tumor marker indicators were compared between the two groups.Results:The disease control rate(DCR)in Group A was higher than that in Group B(P<0.05).There was no difference in adverse reaction rates between Group A and Group B(P>0.05).Total bilirubin(TBil),aspartate aminotransferase(AST),and alanine aminotransferase(ALT)levels in Group A were lower than those in Group B(P<0.05).Carcinoembryonic antigen(CEA),alpha-fetoprotein(AFP),and alpha-L-fucosidase(AFU)levels in Group A were also lower than those in Group B(P<0.05).Conclusion:Intermediate and advanced liver cancer patients receiving interventional therapy combined with lenvatinib and sintilimab showed reduced tumor marker levels,lessened liver function damage,and a high disease control rate and treatment safety.展开更多
Objective:To analyze the clinical efficacy of hepatic artery chemoembolization in the treatment of advanced liver cancer.Methods:124 patients with advanced liver cancer admitted to our hospital from September 2019 to ...Objective:To analyze the clinical efficacy of hepatic artery chemoembolization in the treatment of advanced liver cancer.Methods:124 patients with advanced liver cancer admitted to our hospital from September 2019 to November 2020 were selected as the research subjects of this paper.The patients with advanced liver cancer were divided into experimental group and control group.The control group was treated with radiofrequency ablation alone,and the experimental group was administered hepatic arterial chemoembolization.The improvement in physical indicators and the incidence of adverse reactions between the two groups were compared.Results:The alpha-fetoprotein(AFP)index and serum total bilirubin(TBIL)index of the experimental group were lower than those of the control group,and the alanine aminotransferase(ALT)index was higher than that of the control group.There were differences in the comparison of liver function indices between the two groups which were statistically significant.After treatment,there were 3 cases of fever,4 cases of vomiting,8 cases of bone marrow transplantation,4 cases of abdominal pain,2 cases of proteinuria,and 1 case of diarrhea occurred in the experimental group;whereas there were 6 cases of fever,8 cases of vomiting,14 cases of bone marrow transplantation,7 cases of abdominal pain,5 cases of proteinuria,and 6 cases of diarrhea occurred in the control group.The difference in incidence of adverse reactions between patients after different treatment interventions was statistically significant.Analyzing the remission rate of tumor diseases in patients,the remission rate of the experimental group was higher than that of the control group,and the difference in the remission rate between the two groups of patients was statistically significant.Conclusion:The implementation of hepatic arterial chemoembolization for patients with advanced liver cancer can promote the improvement of the patient's short-term treatment efficacy,enhance the liver functions of the patient,reduce the incidence of adverse reactions,improve the efficiency of the patient's body rehabilitation,and enhance the quality of life of the patient after treatment.展开更多
Aiming at starting the ball rolling and contributing humble effort to promote CTM(Chinese traditional medicine),we performed the present study to assess the therapy response of Chinese herbal decoction compared to con...Aiming at starting the ball rolling and contributing humble effort to promote CTM(Chinese traditional medicine),we performed the present study to assess the therapy response of Chinese herbal decoction compared to conventional therapy on critical ill patients of advanced liver cancer.A total of 6 patients(1 female and 5 males)with histologically confirmed liver cancer were included in this retrospective observational clinical trial.We administered Chinese medicine(Gan Decoction,mixed with a variety of effective herbal components)to help them to recover from poor condition.In the meantime,conventional treatment of surgical resection and artery catheterization chemotherapy was applied in cases compared.In 3 cases of CTM combined treatment,the tumor marker level decreased.Residual intrahepatic metastatic sites reduced according to ultrasonography/CT imaging,and the patients felt free from the complaint of abdominal discomfort.The quality of life has been improved,we managed to have prolonged the PFS(Progression-Free-Survival)and TTP(Time-to-Progression)from the onset to date.While in 3 cases with conventional treatment only of surgical resection and artery catheterization chemotherapy,we were not able to decrease the level of tumor marker,metastatic lesions increased according to ultrasonography/CT imaging,and the patient's condition worsen more.We failed in having prolonged the PFS and TTP in the compared cases of conventional treatment only.The retrospective clinical study showed no OS(overall survival)benefit for liver cancer patients treated with Gan Decoction,while the QOL(quality of life)evaluation seemed to predict survival better.Chinese herbs might be an additional choice with its better benefits and tolerability in the treatment of primary liver cancer.展开更多
基金Medical Research Project of Xi’an Science and Technology Bureau“Molecular Mechanism of miR-1305 Competitive Endogenous circRNA in the Development of Liver Cancer”(Project No.22YXYJ0134)General Project of Key Research and Development Program of Shaanxi Provincial Department of Science and Technology“Mechanism Study on the Inhibition of Liver Cancer Invasion and Metastasis by Downregulating METTL3 and Reducing the m6A Modification Level of MMP3 with Honokiol”(Project No.2023-YBSF-631)。
文摘Objective:To evaluate the predictive value of secreted phosphoprotein 1(SPP1)gene expression for postoperative survival in patients with advanced liver cancer undergoing hepatic artery interventional chemoembolization treatment.Method:Bioinformatics methods,including gene ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway analysis,were used to identify genes related to survival prognosis in hepatocellular carcinoma(HCC)patients.A retrospective analysis of 115 advanced liver cancer patients treated between January 2016 and October 2017 was conducted.Patients were categorized into SPP1 high-expression(n=89)and low-expression groups(n=26).Additionally,115 healthy individuals served as the control group.The relationship between SPP1 expression and clinical pathological features was analyzed.A 60-month follow-up and logistic regression analysis identified risk factors affecting survival.Results:SPP1 mRNA expression was significantly higher in liver cancer patients compared to healthy controls(P<0.05).SPP1 expression levels were significantly associated with tumor size,Child-Pugh grading,lymph node metastasis,and BCLC staging(P<0.05).High SPP1 expression,along with tumor size,Child-Pugh grading,lymph node metastasis,and BCLC staging,were independent risk factors for survival(P<0.05).The 60-month survival rate was 17.39%,with a median survival of 40 months in the low-expression group versus 18 months in the high-expression group(P<0.05).Conclusion:SPP1 expression is significantly upregulated in advanced liver cancer patients and has predictive value for postoperative survival following hepatic artery chemoembolization treatment.SPP1,combined with clinical indicators such as tumor size,Child-Pugh grading,lymph node metastasis,and BCLC staging,may serve as a prognostic biomarker for interventional treatment outcomes.
文摘Objective:To observe the control effect of interventional therapy combined with lenvatinib and sintilimab in patients with intermediate and advanced liver cancer.Methods:82 patients with intermediate and advanced liver cancer who visited from January 2022 to January 2025 were selected as samples and randomly divided into two groups.Group A received interventional therapy combined with lenvatinib and sintilimab,while Group B received interventional therapy combined with lenvatinib.Disease remission rate,adverse reactions,liver function indicators,and tumor marker indicators were compared between the two groups.Results:The disease control rate(DCR)in Group A was higher than that in Group B(P<0.05).There was no difference in adverse reaction rates between Group A and Group B(P>0.05).Total bilirubin(TBil),aspartate aminotransferase(AST),and alanine aminotransferase(ALT)levels in Group A were lower than those in Group B(P<0.05).Carcinoembryonic antigen(CEA),alpha-fetoprotein(AFP),and alpha-L-fucosidase(AFU)levels in Group A were also lower than those in Group B(P<0.05).Conclusion:Intermediate and advanced liver cancer patients receiving interventional therapy combined with lenvatinib and sintilimab showed reduced tumor marker levels,lessened liver function damage,and a high disease control rate and treatment safety.
文摘Objective:To analyze the clinical efficacy of hepatic artery chemoembolization in the treatment of advanced liver cancer.Methods:124 patients with advanced liver cancer admitted to our hospital from September 2019 to November 2020 were selected as the research subjects of this paper.The patients with advanced liver cancer were divided into experimental group and control group.The control group was treated with radiofrequency ablation alone,and the experimental group was administered hepatic arterial chemoembolization.The improvement in physical indicators and the incidence of adverse reactions between the two groups were compared.Results:The alpha-fetoprotein(AFP)index and serum total bilirubin(TBIL)index of the experimental group were lower than those of the control group,and the alanine aminotransferase(ALT)index was higher than that of the control group.There were differences in the comparison of liver function indices between the two groups which were statistically significant.After treatment,there were 3 cases of fever,4 cases of vomiting,8 cases of bone marrow transplantation,4 cases of abdominal pain,2 cases of proteinuria,and 1 case of diarrhea occurred in the experimental group;whereas there were 6 cases of fever,8 cases of vomiting,14 cases of bone marrow transplantation,7 cases of abdominal pain,5 cases of proteinuria,and 6 cases of diarrhea occurred in the control group.The difference in incidence of adverse reactions between patients after different treatment interventions was statistically significant.Analyzing the remission rate of tumor diseases in patients,the remission rate of the experimental group was higher than that of the control group,and the difference in the remission rate between the two groups of patients was statistically significant.Conclusion:The implementation of hepatic arterial chemoembolization for patients with advanced liver cancer can promote the improvement of the patient's short-term treatment efficacy,enhance the liver functions of the patient,reduce the incidence of adverse reactions,improve the efficiency of the patient's body rehabilitation,and enhance the quality of life of the patient after treatment.
文摘Aiming at starting the ball rolling and contributing humble effort to promote CTM(Chinese traditional medicine),we performed the present study to assess the therapy response of Chinese herbal decoction compared to conventional therapy on critical ill patients of advanced liver cancer.A total of 6 patients(1 female and 5 males)with histologically confirmed liver cancer were included in this retrospective observational clinical trial.We administered Chinese medicine(Gan Decoction,mixed with a variety of effective herbal components)to help them to recover from poor condition.In the meantime,conventional treatment of surgical resection and artery catheterization chemotherapy was applied in cases compared.In 3 cases of CTM combined treatment,the tumor marker level decreased.Residual intrahepatic metastatic sites reduced according to ultrasonography/CT imaging,and the patients felt free from the complaint of abdominal discomfort.The quality of life has been improved,we managed to have prolonged the PFS(Progression-Free-Survival)and TTP(Time-to-Progression)from the onset to date.While in 3 cases with conventional treatment only of surgical resection and artery catheterization chemotherapy,we were not able to decrease the level of tumor marker,metastatic lesions increased according to ultrasonography/CT imaging,and the patient's condition worsen more.We failed in having prolonged the PFS and TTP in the compared cases of conventional treatment only.The retrospective clinical study showed no OS(overall survival)benefit for liver cancer patients treated with Gan Decoction,while the QOL(quality of life)evaluation seemed to predict survival better.Chinese herbs might be an additional choice with its better benefits and tolerability in the treatment of primary liver cancer.
